AstraZeneca/AZN
£120.74
-0.3%-
1D1W1MYTD1YMAX
About AstraZeneca
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
Ticker
AZN
Sector
Healthcare
Trading on
LSE
Industry
Biotechnology & Drugs
CEO
Pascal Soriot
Employees
89,900
Headquarters
Cambridge, United Kingdom
Website
www.astrazeneca.com
AstraZeneca Metrics
BasicAdvanced
£238B
Market cap
37.82
P/E ratio
£4.06
EPS
0.36
Beta
£2.90
Dividend rate
1.88%
Dividend yield
Price and volume
Market cap
£238B
Beta
0.3648
52-week high
£158.59
52-week low
£119.92
Average daily volume
2.7M
Dividend rate
£2.90
Financial strength
Current ratio
0.886
Quick ratio
0.701
Long term debt to equity
75.364
Total debt to equity
92.271
Enterprise value to free cash flow
85.363
Interest coverage (TTM)
6.53%
Management effectiveness
Return on assets (TTM)
6.37%
Return on equity (TTM)
17.29%
Return on investment (TTM)
8.73%
Valuation
Price to earnings (TTM)
37.824
Price to revenue (TTM)
4.994
Price to book
6.35
Price to free cash flow (TTM)
180.411
Five year average dividend yield
2.44%
Dividend yield (TTM)
1.89%
Forward dividend yield
1.88%
Growth
Revenue change (TTM)
10.93%
Earnings per share change (TTM)
43.75%
3-year revenue growth
19.84%
3-year earnings per share growth
16.13%
3-year dividend per share growth
0.81%
What the Analysts think about AstraZeneca
Analyst Ratings
Majority rating from 31 analysts.
Price Targets
Average projection from 27 analysts.
High £176.81
Low £61.42
£120.74
Current price
£128.93
Average price target
AstraZeneca Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$13B
5.45%
Net income
US$2.2B
126.98%
Profit margin
17.18%
115.29%
AstraZeneca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
US$2.15
US$1.73
US$1.45
US$2.06
-
Expected
US$1.95
US$1.62
US$1.49
US$1.91
US$1.96
Surprise
10.01%
6.92%
-2.82%
8.05%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £238B as of May 20, 2024.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 37.82 as of May 20, 2024.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of May 20, 2024, the dividend rate is £2.89787 and the yield is 1.88%. AstraZeneca has a payout ratio of 0% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the AstraZeneca stock price target?
The target price for AstraZeneca (AZN) stock is £128.93, which is 6.78% above the current price of £120.74. This is an average based on projections from 27 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell AstraZeneca stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.